Meier M

No ORCID on file · 1 paper in corpus · active 2011

Study types

  • article 1
article 2011
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
Gynecologic oncology ·doi:10.1016/j.ygyno.2011.02.022

ObjectiveAbout 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many …